Previous close | 118.00 |
Open | 118.40 |
Bid | 121.00 x 100000 |
Ask | 121.20 x 100000 |
Day's range | 118.00 - 118.60 |
52-week range | 90.70 - 123.20 |
Volume | |
Avg. volume | 351 |
Market cap | 300.357B |
Beta (5Y monthly) | 0.40 |
PE ratio (TTM) | 140.48 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 2.84 (2.41%) |
Ex-dividend date | 14 Mar 2024 |
1y target est | N/A |
Merck ( NYSE:MRK ) First Quarter 2024 Results Key Financial Results Revenue: US$15.8b (up 8.9% from 1Q 2023). Net...
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
After topping expectations with first quarter revenue and adjusted earnings last week, Merck & Co Inc (NYSE: MRK) just reported encouraging data from its Phase III gastric cancer treatment trial after ending 2023 with good news from its combined treatment with Moderna Inc (NASDAQ: MRNA) in fighting melanoma. Merck reported improvement in cancer patients receiving its Keytruda regimen. Enrolling 698 subjects, the trial evaluated the effect of a treatment that combines Merck’s immunotherapy blockb